[go: up one dir, main page]

RU2008101365A - Композиции и способы диагностики и лечения опухоли - Google Patents

Композиции и способы диагностики и лечения опухоли Download PDF

Info

Publication number
RU2008101365A
RU2008101365A RU2008101365/13A RU2008101365A RU2008101365A RU 2008101365 A RU2008101365 A RU 2008101365A RU 2008101365/13 A RU2008101365/13 A RU 2008101365/13A RU 2008101365 A RU2008101365 A RU 2008101365A RU 2008101365 A RU2008101365 A RU 2008101365A
Authority
RU
Russia
Prior art keywords
antibody
seq
protein
tumor
sequence
Prior art date
Application number
RU2008101365/13A
Other languages
English (en)
Other versions
RU2430112C2 (ru
Inventor
Марк ДЕННИС (US)
Марк ДЕННИС
Уилльям МАЛЛЕТ (US)
Уилльям МАЛЛЕТ
Пол ПОЛЕЙКИС (US)
Пол ПОЛЕЙКИС
Original Assignee
Дженентек, Инк. (Us)
Дженентек, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дженентек, Инк. (Us), Дженентек, Инк. filed Critical Дженентек, Инк. (Us)
Publication of RU2008101365A publication Critical patent/RU2008101365A/ru
Application granted granted Critical
Publication of RU2430112C2 publication Critical patent/RU2430112C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/13—Hollow or container type article [e.g., tube, vase, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

1. Выделенное антитело, содержащее по меньшей мере одну HVR-последовательность, выбранную из группы, включающей: ! (а) последовательность HVR-L1, выбранную из одной из последовательностей, представленных в SEQ ID NO:14-34; ! (б) последовательность HVR-L2, выбранную из одной из последовательностей, представленных SEQ ID NO:35-58; ! (в) последовательность HVR-L3, выбранную из одной из последовательностей, представленных в SEQ ID NO:59-73; ! (г) последовательность HVR-H1, выбранную из одной из последовательностей, представленных в SEQ ID NO:74-93; ! (д) последовательность HVR-H2, выбранную из одной из последовательностей, представленных в SEQ ID NO:94-112; и ! (е) последовательность HVR-H3, выбранную из одной из последовательностей, представленных в SEQ ID NO:113-118. ! 2. Выделенное антитело по п.1, дополнительно содержащее последовательность акцепторного человеческого консенсусного каркасного участка HV, выбранную из одной из последовательностей, представленных в SEQ ID NO:184-193. ! 3. Выделенное антитело по п.1, дополнительно содержащее последовательность акцепторного человеческого консенсусного каркасного участка HL, выбранную из одной из последовательностей, представленных в SEQ ID NO:194-197. ! 4. Выделенное антитело по п.1, дополнительно содержащее последовательность акцепторного человеческого консенсусного каркасного участка HV, выбранную из одной из последовательностей, представленных в SEQ ID NO:184-193, и последовательность акцепторного человеческого консенсусного каркасного участка HL, выбранную из одной из последовательностей, представленных в SEQ ID NO:194-197. ! 5. Антитело по п.1, представляющее собой фрагмент антитела. ! 6. Антитело по п.1, представляющее собой химерное или гуманизированное антите�

Claims (36)

1. Выделенное антитело, содержащее по меньшей мере одну HVR-последовательность, выбранную из группы, включающей:
(а) последовательность HVR-L1, выбранную из одной из последовательностей, представленных в SEQ ID NO:14-34;
(б) последовательность HVR-L2, выбранную из одной из последовательностей, представленных SEQ ID NO:35-58;
(в) последовательность HVR-L3, выбранную из одной из последовательностей, представленных в SEQ ID NO:59-73;
(г) последовательность HVR-H1, выбранную из одной из последовательностей, представленных в SEQ ID NO:74-93;
(д) последовательность HVR-H2, выбранную из одной из последовательностей, представленных в SEQ ID NO:94-112; и
(е) последовательность HVR-H3, выбранную из одной из последовательностей, представленных в SEQ ID NO:113-118.
2. Выделенное антитело по п.1, дополнительно содержащее последовательность акцепторного человеческого консенсусного каркасного участка HV, выбранную из одной из последовательностей, представленных в SEQ ID NO:184-193.
3. Выделенное антитело по п.1, дополнительно содержащее последовательность акцепторного человеческого консенсусного каркасного участка HL, выбранную из одной из последовательностей, представленных в SEQ ID NO:194-197.
4. Выделенное антитело по п.1, дополнительно содержащее последовательность акцепторного человеческого консенсусного каркасного участка HV, выбранную из одной из последовательностей, представленных в SEQ ID NO:184-193, и последовательность акцепторного человеческого консенсусного каркасного участка HL, выбранную из одной из последовательностей, представленных в SEQ ID NO:194-197.
5. Антитело по п.1, представляющее собой фрагмент антитела.
6. Антитело по п.1, представляющее собой химерное или гуманизированное антитело.
7. Антитело по п.1, конъюгированное с ингибирующим рост агентом.
8. Антитело по п.1, конъюгированное с цитотоксическим агентом.
9. Антитело по п.8, в котором цитотоксический агент выбран из группы, включающей токсины, антибиотики, радиоактивные изотопы или нуклеолитические ферменты.
10. Антитело по п.8, в котором цитотоксический агент представляет собой токсин.
11. Антитело по п.10, в котором токсин выбран из группы, включающей майтансиноид и калихеамицин.
12. Антитело по п.10, в котором токсин представляет собой майтансиноид.
13. Антитело по п.1, которое продуцируется в бактериях.
14. Антитело по п.1, которое продуцируется в СНО-клетках.
15. Антитело по п.1, которое индуцирует гибель клетки, с которой оно связывается.
16. Антитело по п.15, где клетка представляет собой клетку рака яичника.
17. Антитело по п.1, которое несет обнаруживаемую метку.
18. Выделенное антитело, которое содержит по меньшей мере один из гипервариабельных участков любого антитела, продуцируемого любой из линий клеток гибридомы, представленных в таблице 11.
19. Моноклональное антитело, продуцируемое любой из линий клеток гибридомы, представленных в таблице 11.
20. Клетка гибридомы, которая продуцирует моноклональное антитело, связывающееся в полипептидом ТАТ10772.
21. Способ идентификации первого антитела, которое связывается с антигенным эпитопом ТАТ10772, сшитым со вторым антителом, где второе антитело представляет собой любое из антител по пп.1, 18 или 19, заключающийся в том, что определяют способностью первого антитела блокировать связывание второго антитела с полипептидом ТАТ10772, где способность первого антитела блокировать связывание второго антитела с полипептидом ТАТ10772 составляет по меньшей мере 40%, и при использовании одинаковых концентраций антител свидетельствует о том, что первое антитело обладает способностью связываться с эпитопом, с которым связывается второе антитело.
22. Способ ингибирования роста клетки, которая экспрессирует белок, имеющий аминокислотную последовательность, представленную в SEQ ID NO:2, заключающийся в том, что приводят в контакт клетку с антителом по одному из пп.1, 18 или 19, при этом связывание антитела с белком вызывает ингибирование роста указанной клетки.
23. Способ по п.22, в котором клетка представляет собой клетку рака яичника.
24. Способ терапевтического лечения млекопитающего, которое имеет злокачественную опухоль, содержащую клетки, которые экспрессируют белок, имеющий аминокислотную последовательность, которая представлена в SEQ ID NO:2, заключающийся в том, что вводят млекопитающему в терапевтически эффективном количестве антитело по одному из пп.1, 18 или 19, осуществляя тем самым эффективное лечение млекопитающего.
25. Способ по п.4, в котором злокачественная опухоль представляет собой опухоль яичника.
26. Способ определения присутствия белка ТАТ10772 в образце, в котором предполагается присутствие указанного белка, заключающийся в том, что обрабатывают образец антителом по одному из пп.1, 18 или 19 и определяют связывание антитела с белком в образце, где связывание антитела с белком свидетельствует о присутствии указанного белка в образце.
27. Способ по п.26, в котором образец содержит клетку, которая, как предполагается, экспрессирует указанный белок.
28. Способ по п.27, в котором клетка представляет собой клетку рака яичника.
29. Способ по п.26, в котором антитело несет обнаруживаемую метку.
30. Способ диагностики присутствия опухоли у млекопитающего, заключающийся в том, что определяют уровень экспрессии гена, кодирующего белок, который имеет аминокислотную последовательность, представленную в SEQ ID NO:2, в тест-образце клеток ткани, полученных из организма млекопитающего, и в контрольном образце клеток, полученных из такой же ткани, для которых известно, что они являются здоровыми, где более высокий уровень экспрессии указанного белка в тест-образце по сравнению с контрольным образцом свидетельствует о присутствии опухоли у млекопитающего, из организма которого получен тест-образец.
31. Способ по п.30, в котором стадия определения уровня экспрессии гена, кодирующего указанный белок, заключается в применении олигонуклеотида в гибридизации in situ или РВ-ПЦР-анализе.
32. Способ по п.30, в котором стадия определения уровня экспрессии гена, кодирующего указанный белок, заключается в применении антитела в иммуногистохимическом анализе или анализе методом Вестерн-блоттинга.
33. Способ по п.30, в котором опухоль представляет собой опухоль яичника, молочной железы или поджелудочной железы.
34. Способ диагностического выявления опухоли у млекопитающего, заключающийся в том, что приводят в контакт тест-образец клеток ткани, полученных из организма млекопитающего, с антителом по одному из пп.1, 18 или 19 и выявляют образование комплекса между антителом и белком ТАТ10772 в тест-образце, где образование комплекса свидетельствует о присутствии опухоли в организме млекопитающего.
35. Способ по п.34, в котором тест-образец клеток ткани получают из организма индивидуума, у которого предполагается наличие злокачественной опухоли.
36. Способ по п.35, в котором злокачественная опухоль представляет собой опухоль яичника, молочной железы или поджелудочной железы.
RU2008101365/10A 2005-06-20 2006-06-14 Композиции и способы диагностики и лечения опухоли RU2430112C2 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US69209205P 2005-06-20 2005-06-20
US60/692,092 2005-06-20
US79395106P 2006-04-21 2006-04-21
US60/793,951 2006-04-21

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2009136946/10A Division RU2423382C1 (ru) 2005-06-20 2006-06-14 Композиции и способы диагностики и лечения опухоли

Publications (2)

Publication Number Publication Date
RU2008101365A true RU2008101365A (ru) 2009-07-27
RU2430112C2 RU2430112C2 (ru) 2011-09-27

Family

ID=37595671

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2008101365/10A RU2430112C2 (ru) 2005-06-20 2006-06-14 Композиции и способы диагностики и лечения опухоли
RU2009136946/10A RU2423382C1 (ru) 2005-06-20 2006-06-14 Композиции и способы диагностики и лечения опухоли

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2009136946/10A RU2423382C1 (ru) 2005-06-20 2006-06-14 Композиции и способы диагностики и лечения опухоли

Country Status (23)

Country Link
US (8) US7989595B2 (ru)
EP (2) EP2135881B1 (ru)
JP (2) JP5196654B2 (ru)
KR (3) KR20100084706A (ru)
CN (1) CN101948541B (ru)
AT (1) ATE523525T1 (ru)
AU (2) AU2006262603B2 (ru)
BR (2) BRPI0613382A8 (ru)
CA (1) CA2611778C (ru)
CR (2) CR9672A (ru)
DK (1) DK2135881T3 (ru)
EC (1) ECSP088122A (ru)
ES (1) ES2373080T3 (ru)
IL (1) IL187343A (ru)
MA (1) MA29615B1 (ru)
MX (1) MX2007016322A (ru)
NO (1) NO20080361L (ru)
NZ (2) NZ563370A (ru)
PL (1) PL2135881T3 (ru)
PT (1) PT2135881E (ru)
RU (2) RU2430112C2 (ru)
SG (1) SG155947A1 (ru)
WO (1) WO2007001851A2 (ru)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
EP2478912B1 (en) 2003-11-06 2016-08-31 Seattle Genetics, Inc. Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
EP3505191A1 (en) 2004-11-12 2019-07-03 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the n terminus
USRE47223E1 (en) 2005-06-20 2019-02-05 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AU2006269422B2 (en) 2005-07-07 2012-12-06 Seagen Inc. Monomethylvaline compounds having phenylalanine side-chain modifications at the C-terminus
US8871720B2 (en) 2005-07-07 2014-10-28 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
AR065573A1 (es) 2007-03-02 2009-06-17 Boehringer Ingelheim Int Metodo de produccion de proteinas heterologas por expresion de una proteina con dominio de trasnferencia de lipido relacionada con proteina reguladora de la esteroidogenesis aguda start.
PE20090245A1 (es) * 2007-05-08 2009-03-17 Genentech Inc Anticuerpos anti-muc16 disenados con cisteina y conjugados de anticuerpos y farmacos
CN101802013B (zh) 2007-07-16 2014-07-02 健泰科生物技术公司 人源化抗cd79b抗体和免疫偶联物及使用方法
PL2176296T3 (pl) 2007-07-16 2012-07-31 Genentech Inc Przeciwciała anty-CD79B i immunokoniugaty i sposoby stosowania
PT2247620T (pt) 2008-01-31 2016-08-23 Genentech Inc Anticorpos e imunoconjugados anti-cd79b e métodos de utilização
DK2752428T3 (da) * 2008-06-25 2020-02-24 Novartis Ag Humanisering af kanin-antistoffer under anvendelse af et universelt antistof-framework
AU2013203004C1 (en) * 2008-06-25 2022-01-20 Novartis Ag Humanization of rabbit antibodies using a universal antibody framework
US8673310B2 (en) 2008-06-25 2014-03-18 ESBA Tech, an Alcon Biomedical Research Unit LLC Stable and soluble antibodies inhibiting TNFα
AU2020201002B2 (en) * 2008-06-25 2022-04-07 Novartis Ag Humanization of rabbit antibodies using a universal antibody framework
PT2752428T (pt) * 2008-06-25 2020-02-14 Novartis Ag Humanização de anticorpos de coelho com utilização de um framework de anticorpos universal
CN103599541A (zh) 2008-09-10 2014-02-26 弗·哈夫曼-拉罗切有限公司 用于防止蛋白质氧化降解的组合物和方法
HRP20150965T1 (hr) 2009-03-25 2015-11-06 Genentech, Inc. Anti-fgr3 protutijela i metode koje ih koriste
SG174930A1 (en) * 2009-04-01 2011-11-28 Genentech Inc Anti-fcrh5 antibodies and immunoconjugates and methods of use
TW201105793A (en) 2009-05-05 2011-02-16 Boehringer Ingelheim Int CHO/CERT cell lines
WO2011050188A1 (en) 2009-10-22 2011-04-28 Genentech, Inc. Anti-hepsin antibodies and methods using same
US8968740B2 (en) * 2009-11-13 2015-03-03 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
CA2781887C (en) * 2009-11-30 2018-03-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
CA2792125C (en) 2010-03-22 2019-02-12 Genentech, Inc. Compositions and methods useful for stabilizing protein-containing formulations
HUE032519T2 (en) * 2010-03-26 2017-09-28 Memorial Sloan Kettering Cancer Center Antibodies to MUC16 and a procedure for its use
WO2011139718A1 (en) 2010-05-03 2011-11-10 Genentech, Inc. Compositions and methods useful for reducing the viscosity of protein-containing formulations
ES2751381T3 (es) 2010-06-24 2020-03-31 Hoffmann La Roche Composiciones y procedimientos que contienen alquilglucósidos para estabilizar formulaciones que contienen proteínas
UY33679A (es) 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
CN102585010A (zh) * 2011-01-16 2012-07-18 董贵俊 一种检测重组人碱性成纤维细胞生长因子(rhbFGF)的免疫胶乳微球及其制备方法
US10260089B2 (en) 2012-10-29 2019-04-16 The Research Foundation Of The State University Of New York Compositions and methods for recognition of RNA using triple helical peptide nucleic acids
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
MY183572A (en) * 2013-03-15 2021-02-26 Regeneron Pharma Biologically active molecules, conjugates thereof, and therapeutic uses
KR101502680B1 (ko) * 2013-04-01 2015-03-17 중앙대학교 산학협력단 난소과립종양세포 진단용 펩타이드 및 이의 용도
AR096687A1 (es) 2013-06-24 2016-01-27 Genentech Inc Anticuerpos anti-fcrh5
MX2016001862A (es) 2013-08-12 2016-08-03 Genentech Inc Compuestos de conjugado anticuerpo-farmaco dimerico de 1-(clorometil)-2,3-dihidro-1h-benzo[e]indol, y metodos de uso y tratamiento.
KR102354207B1 (ko) 2013-12-16 2022-01-20 제넨테크, 인크. 펩티드모방체 화합물 및 그의 항체-약물 접합체
MX2016007826A (es) 2013-12-16 2017-03-31 Genentech Inc Compuestos peptidomimeticos y sus conjugados de anticuerpo-farmaco.
KR20160092024A (ko) 2013-12-16 2016-08-03 제넨테크, 인크. 1-(클로로메틸)-2,3-디히드로-1H-벤조[e]인돌 이량체 항체-약물 접합체 화합물, 및 사용 및 치료 방법
KR102433591B1 (ko) 2013-12-17 2022-08-18 제넨테크, 인크. 항-cd3 항체 및 이의 사용 방법
HRP20200924T8 (hr) 2014-09-23 2023-07-21 F. Hoffmann - La Roche Ag Postupak primjene imunokonjugata anti-cd79b
US10208120B2 (en) 2014-11-05 2019-02-19 Genentech, Inc. Anti-FGFR2/3 antibodies and methods using same
CN105675735B (zh) * 2014-11-19 2018-07-17 上海市第六人民医院 乳腺癌诊断标记物组合、应用及其测定方法
KR20170086121A (ko) 2014-12-03 2017-07-25 제넨테크, 인크. 4급 아민 화합물 및 그의 항체-약물 접합체
BR112017020149A8 (pt) 2015-03-27 2023-05-02 Regeneron Pharma Derivados de maitansinoide, conjugados dos mesmos e métodos de uso
WO2016205176A1 (en) 2015-06-15 2016-12-22 Genentech, Inc. Antibodies and immunoconjugates
AU2016280102B2 (en) 2015-06-16 2022-06-16 Genentech, Inc. Humanized and affinity matured antibodies to FcRH5 and methods of use
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
MY198605A (en) 2016-01-25 2023-09-08 Regeneron Pharma Maytansinoid derivatives conjugates thereof, and methods of use
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
JP2019522633A (ja) 2016-05-20 2019-08-15 ジェネンテック， インコーポレイテッド Ｐｒｏｔａｃ抗体コンジュゲート及び使用方法
TWI823836B (zh) 2016-07-08 2023-12-01 美商建南德克公司 人類副睪蛋白４（ｈｅ４）用於評定癌症治療反應性之用途
WO2018148486A1 (en) 2017-02-10 2018-08-16 The Trustees Of The University Of Pennsylvania Anti-factor d antibodies and uses thereof
WO2018209239A1 (en) 2017-05-11 2018-11-15 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US20210139589A1 (en) * 2017-06-22 2021-05-13 Apexigen, Inc Anti-vista antibodies and methods of use
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
WO2019084030A1 (en) 2017-10-24 2019-05-02 Genentech, Inc. (4-HYDROXYPYRROLIDIN-2-YL) -HYDROXAMATE COMPOUNDS AND METHODS OF USE
EP3700901A1 (en) 2017-10-24 2020-09-02 Genentech, Inc. (4-hydroxypyrrolidin-2-yl)-heterocyclic compounds and methods of use thereof
CN108181214B (zh) * 2018-02-09 2020-06-30 北京爱泰浦生物医药科技有限责任公司 使用atap肽治疗疾病的方法和组合物
WO2019183523A1 (en) 2018-03-23 2019-09-26 Genentech, Inc. Hetero-bifunctional degrader compounds and their use as modulators of targeted ubiquination (vhl)
KR20210021493A (ko) 2018-06-04 2021-02-26 프레시전 인코포레이티드 Muc16 특이적 키메라 항원 수용체 및 그의 용도
EP3844192A1 (en) 2018-08-30 2021-07-07 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
TWI888359B (zh) 2018-09-11 2025-07-01 瑞士商赫孚孟拉羅股份公司 噻吩并－三唑并－二氮呯醋酸酯
CN113660953A (zh) 2019-04-01 2021-11-16 豪夫迈·罗氏有限公司 用于稳定含蛋白质制剂的组合物和方法
CN109988086B (zh) * 2019-04-04 2021-06-18 三峡大学 一种小分子抑制剂azin30及其在制药中的应用
WO2020247054A1 (en) 2019-06-05 2020-12-10 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
WO2022182415A1 (en) 2021-02-24 2022-09-01 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof
US12060148B2 (en) 2022-08-16 2024-08-13 Honeywell International Inc. Ground resonance detection and warning system and method
EP4615874A1 (en) 2022-11-10 2025-09-17 Immuvia Inc Cytotoxic bispecific antibodies binding to dr5 and muc16 and uses thereof
WO2025036848A1 (en) 2023-08-11 2025-02-20 Wuxi Biologics (Shanghai) Co., Ltd. Anti-muc16 antibodies and uses thereof
TW202523694A (zh) 2023-11-17 2025-06-16 中國大陸商上海藥明生物技術有限公司 抗muc16抗體及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9424449D0 (en) 1994-12-02 1995-01-18 Wellcome Found Antibodies
US6037454A (en) * 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
WO1998035698A1 (fr) * 1997-02-12 1998-08-20 Chugai Seiyaku Kabushiki Kaisha Remedes contre les tumeurs lymphocitaires
DE69836729T2 (de) * 1997-04-07 2007-12-13 Genentech, Inc., South San Francisco Anti-vefg antibodies
US7083950B2 (en) * 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. High affinity fusion proteins and therapeutic and diagnostic methods for use
US20020119158A1 (en) 1998-12-17 2002-08-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US20030078399A1 (en) 2001-05-11 2003-04-24 Sloan-Kettering Institute For Cancer Research Nucleic acid sequence encoding ovarian antigen, CA125, and uses thereof
US7803915B2 (en) * 2001-06-20 2010-09-28 Genentech, Inc. Antibody compositions for the diagnosis and treatment of tumor
JP2006502110A (ja) 2002-07-03 2006-01-19 イミュノジェン・インコーポレーテッド 非放出Ｍｕｃ１およびＭｕｃ１６に対する抗体、およびその使用
AU2003294232A1 (en) * 2002-10-16 2004-05-04 Euro-Celtique S.A. Antibodies that bind cell-associated CA 125/O722P and methods of use thereof
MXPA05005237A (es) * 2002-11-15 2005-08-16 Univ Arkansas Gen ca125 y su uso para diagnostico e intervenciones terapeuticas.
ES2729974T3 (es) 2003-01-23 2019-11-07 Ono Pharmaceutical Co Anticuerpo específico de PD-1 y CD3 humanas
EP2478912B1 (en) * 2003-11-06 2016-08-31 Seattle Genetics, Inc. Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
EP2168986A3 (en) * 2004-02-19 2010-07-28 Genentech, Inc. CDR-repaired antibodies
WO2006106912A1 (ja) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha 癌関連抗原アナログペプチド、およびその利用
AR059900A1 (es) 2006-03-17 2008-05-07 Genentech Inc Anticuerpos anti-tat226 e inmunoconjugados

Also Published As

Publication number Publication date
CR20130455A (es) 2013-10-22
NO20080361L (no) 2008-03-25
NZ563370A (en) 2010-10-29
ECSP088122A (es) 2008-02-20
PT2135881E (pt) 2011-12-21
CR9672A (es) 2008-07-31
KR20100084706A (ko) 2010-07-27
DK2135881T3 (da) 2011-12-05
EP2135881A1 (en) 2009-12-23
RU2009136946A (ru) 2011-04-20
BRPI0613382A8 (pt) 2018-01-02
BRPI0622254A2 (pt) 2011-08-09
RU2423382C1 (ru) 2011-07-10
US8449883B2 (en) 2013-05-28
KR100970824B1 (ko) 2010-07-16
MA29615B1 (fr) 2008-07-01
US7989595B2 (en) 2011-08-02
KR20080017104A (ko) 2008-02-25
CA2611778A1 (en) 2007-01-04
AU2010251794A1 (en) 2011-01-13
JP2012188449A (ja) 2012-10-04
NZ583206A (en) 2011-07-29
US20140314794A1 (en) 2014-10-23
US20160296634A1 (en) 2016-10-13
ES2373080T3 (es) 2012-01-31
KR101103108B1 (ko) 2012-01-04
US20140050744A1 (en) 2014-02-20
SG155947A1 (en) 2009-10-29
WO2007001851A2 (en) 2007-01-04
JP2008546780A (ja) 2008-12-25
US20110177103A1 (en) 2011-07-21
WO2007001851A3 (en) 2007-03-22
IL187343A0 (en) 2008-04-13
HK1134098A1 (en) 2010-04-16
ATE523525T1 (de) 2011-09-15
KR20090101980A (ko) 2009-09-29
CN101948541B (zh) 2014-08-06
PL2135881T3 (pl) 2012-02-29
AU2006262603B2 (en) 2011-01-06
MX2007016322A (es) 2008-04-07
EP1910419A2 (en) 2008-04-16
US20180344864A1 (en) 2018-12-06
CN101948541A (zh) 2011-01-19
BRPI0613382A2 (pt) 2010-06-29
US20140205616A1 (en) 2014-07-24
US20090041749A1 (en) 2009-02-12
IL187343A (en) 2012-02-29
CA2611778C (en) 2012-11-27
RU2430112C2 (ru) 2011-09-27
JP5196654B2 (ja) 2013-05-15
AU2006262603A1 (en) 2007-01-04
US20120114673A1 (en) 2012-05-10
EP2135881B1 (en) 2011-09-07

Similar Documents

Publication Publication Date Title
RU2008101365A (ru) Композиции и способы диагностики и лечения опухоли
JP5631733B2 (ja) 抗ＥｐＣＡＭ抗体およびその使用
KR102022734B1 (ko) 신규 조절제 및 용법
RU2012140451A (ru) Композиции и способы для диагностики и лечения опухолей
JP2008546780A5 (ru)
CN113527489A (zh) 抗cd73的抗体及其用途
AU2013302620B2 (en) Stem cell enhancing therapeutics
RU2656153C1 (ru) Антитела, специфичные к альфа-энолазе, и способы применения в противоопухолевой терапии
CN107001452B (zh) 用于治疗癌症的抗ck8抗体
EP1648506B1 (en) Method for treating synovial sarcoma
CN113906053B (zh) 抗cea抗体及其应用
CA2936346A1 (en) Antibody targeting cell surface deposited complement protein c3d and use thereof
RU2012151492A (ru) Композиции и способы для диагностики и лечения опухоли
RU2016148616A (ru) Анти-lgr5 антитела и их применение
WO2016052756A1 (ja) 浸潤能の高い癌細胞の検出用又は診断用試薬
CN103130896B (zh) 抗细胞表面异位表达的单克隆抗体及其制备方法和用途
CN113597432B (zh) 抗EpCAM抗体及其应用
CN113801231A (zh) 抗dog-1抗体或其抗原结合片段及其用途
CN102786598B (zh) 抗ercc1 单克隆抗体4f9 及其用途
WO2023227115A1 (en) A method of treating solid tumor
AU2022246948A9 (en) Il-38-specific antibodies
HK40064841A (en) Anti-cea antibody and application thereof
CN117677396A (zh) Il-38特异性抗体
CN102786597A (zh) 抗ercc1单克隆抗体2e12及其用途
HK1148536B (en) Anti-epcam antibody and uses thereof

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20190615